Three‐dimensional cryogel matrix for spheroid formation and anti‐cancer drug screening

2019 ◽  
Vol 108 (2) ◽  
pp. 365-376 ◽  
Author(s):  
Archana Singh ◽  
Prakriti Tayalia
Keyword(s):  
Drug Screening ◽  
Three Dimensional ◽  
Cancer Drug ◽  
Spheroid Formation ◽  
Anti Cancer

Automated tracking of unmarked cells migrating in three-dimensional matrices applied to anti-cancer drug screening

2010 ◽  
Vol 316 (2) ◽  
pp. 181-193 ◽  
Author(s):  
Ivan Adanja ◽  
Olivier Debeir ◽  
Véronique Mégalizzi ◽  
Robert Kiss ◽  
Nadine Warzée ◽  
...  
Keyword(s):  
Drug Screening ◽  
Three Dimensional ◽  
Cancer Drug ◽  
Automated Tracking ◽  
Anti Cancer

scholarly journals Three-dimensional perfused tumour spheroid model for anti-cancer drug screening

2016 ◽  
Vol 38 (8) ◽  
pp. 1389-1395 ◽  
Author(s):  
Xiao Wan ◽  
Zhaohui Li ◽  
Hua Ye ◽  
Zhanfeng Cui
Keyword(s):  
Drug Screening ◽  
Three Dimensional ◽  
Cancer Drug ◽  
Tumour Spheroid ◽  
Anti Cancer

scholarly journals In Situ Vitrification of Lung Cancer Organoids on a Microwell Array

Micromachines ◽  
2021 ◽  
Vol 12 (6) ◽  
pp. 624
Author(s):  
Qiang Liu ◽  
Tian Zhao ◽  
Xianning Wang ◽  
Zhongyao Chen ◽  
Yawei Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Sensitivity ◽  
Simple Procedure ◽  
Three Dimensional ◽  
Cancer Drug ◽  
Microwell Array ◽  
Sensitivity Tests ◽  
Anti Cancer

Three-dimensional cultured patient-derived cancer organoids (PDOs) represent a powerful tool for anti-cancer drug development due to their similarity to the in vivo tumor tissues. However, the culture and manipulation of PDOs is more difficult than 2D cultured cell lines due to the presence of the culture matrix and the 3D feature of the organoids. In our other study, we established a method for lung cancer organoid (LCO)-based drug sensitivity tests on the superhydrophobic microwell array chip (SMAR-chip). Here, we describe a novel in situ cryopreservation technology on the SMAR-chip to preserve the viability of the organoids for future drug sensitivity tests. We compared two cryopreservation approaches (slow freezing and vitrification) and demonstrated that vitrification performed better at preserving the viability of LCOs. Next, we developed a simple procedure for in situ cryopreservation and thawing of the LCOs on the SMAR-chip. We proved that the on-chip cryopreserved organoids can be recovered successfully and, more importantly, showing similar responses to anti-cancer drugs as the unfrozen controls. This in situ vitrification technology eliminated the harvesting and centrifugation steps in conventional cryopreservation, making the whole freeze–thaw process easier to perform and the preserved LCOs ready to be used for the subsequent drug sensitivity test.

Prevascularized, Co-Culture Model for Breast Cancer Drug Development

2012 ◽  
Author(s):  
Lauren Marshall ◽  
Isabel Löwstedt ◽  
Paul Gatenholm ◽  
Joel Berry
Keyword(s):  
Breast Cancer ◽  
Drug Development ◽  
Three Dimensional ◽  
Human Tumor ◽  
3D Models ◽  
Cancer Drug ◽  
Cancer Therapies ◽  
Anti Cancer

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].

Cell sheet-based multilayered liver tumor models for anti-cancer drug screening

2017 ◽  
Vol 40 (2) ◽  
pp. 427-435 ◽  
Author(s):  
Jianing Yang ◽  
Shengjun Zhao ◽  
Yunfei Ji ◽  
Lili Zhao ◽  
Qingzhu Kong ◽  
...  
Keyword(s):  
Drug Screening ◽  
Liver Tumor ◽  
Cell Sheet ◽  
Cancer Drug ◽  
Tumor Models ◽  
Anti Cancer

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4879-4879
Author(s):  
Myoung Woo Lee ◽  
Hye Jin Kim ◽  
Dae Seong Kim ◽  
Meong Hi Son ◽  
Soo Hyun Lee ◽  
...  
Keyword(s):  
Animal Model ◽  
Mouse Model ◽  
Drug Screening ◽  
Scid Mouse ◽  
Lymphoblastic Leukemia ◽  
Cancer Drug ◽  
Screening System ◽  
Bioluminescent Signal ◽  
Anti Cancer

Abstract Abstract 4879 Background. A hematological malignant animal model is an essential tool for evaluating efficacy of anti-cancer drugs and elucidating underlying mechanism of leukemogenesis. Intraperitoneal (IP) and intravenous (IV) xenograft of acute lymphoblastic leukemia (ALL) cells have limited capacity as in vivo anti-cancer drug screening system. Purpose. In this study, we aimed to establish an ALL animal model using NOD/SCID mouse and evaluate efficiency and sensitivity of the model as a preclinical drug screening system. Materials and Methods. Firefly luciferase (fLuc)-gene introduced ALL (ALL/fLuc) cell line and patient-originated ALL cells were transplanted into a tibia of NOD/SCID mouse. We conducted a comparative analysis of intra-bone marrow (IBMT) transplanted leukemia model with IP and IV transplantation of leukemic cells. Results. IBMT of ALL/fLuc cells effectively established a bioluminescent leukemia NOD/SCID mouse model. Upon comparison of IBMT model with IP and IV transplantation models, infusing identical number of ALL/fLuc cells into NOD/SCID mice resulted in IBMT model with evaluable bioluminescent signal, but not in IP and IV models. In IBMT model, bioluminescent signals of ALL/fLuc cells emitted from peripheral blood, tibia and infiltrated organs indicated that leukemia model was established. The changes in these signals' strength reflected dose-dependent cytotoxic effects of vincristine, which allowed leukemia model with evaluable bioluminescent signal to be utilized as a preclinical drug screening system. IBMT leukemia model was also established using primary ALL cells that can provide additional insights for the development of leukemia therapeutics. Conclusion. IBMT of ALL/fLuc cells enables development of leukemia mouse model with the greater bioluminescent sensitivity than IP and IV in NOD/SCID to evaluate candidate for development of anti-cancer drug. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document